(Total Views: 816)
Posted On: 08/30/2017 9:45:02 AM
Post# of 72446
Innovation Pharmaceuticals $IPIX is NOT a one trick pony.
Want to see what a 1 trick pony looks like when they have something go south in their pipeline of one drug for different stuff? (obviously I only glanced at their pipeline).
http://www.otonomy.com/pipeline/clinical-trials/
OTIC down over 82%
$IPIX has 4 FOUR indications under different drugs in progress setting for completion of late stage phase 2 trials. Kevetrin is more of an early stage phase 2 but you get my drift.
The best proof is in a phase 3, and that is what got OTIC imo.
The potential of $IPIX's pipeline will be seen by EOY this year into 1st Q 2018. Count those apples. MC increasing 153% as someone mentioned is not out of the question. Much higher actually imo.
PCYC and KITE come to mind, ACAD as well. Many others if I could get my brain working.
Want to see what a 1 trick pony looks like when they have something go south in their pipeline of one drug for different stuff? (obviously I only glanced at their pipeline).
http://www.otonomy.com/pipeline/clinical-trials/
OTIC down over 82%
$IPIX has 4 FOUR indications under different drugs in progress setting for completion of late stage phase 2 trials. Kevetrin is more of an early stage phase 2 but you get my drift.
The best proof is in a phase 3, and that is what got OTIC imo.
The potential of $IPIX's pipeline will be seen by EOY this year into 1st Q 2018. Count those apples. MC increasing 153% as someone mentioned is not out of the question. Much higher actually imo.
PCYC and KITE come to mind, ACAD as well. Many others if I could get my brain working.
(4)
(0)
